Amgen Articles
ROBERT ATTIYEH
9 May 1994
NEW YORK STOCK COMMENT
2 May 1994
JAPANESE NEWS IN BRIEF
2 May 1994
NEW YORK STOCK COMMENT
25 April 1994
NEW YORK STOCK COMMENT
11 April 1994
JAPANESE COs TOO DEPENDENT ON HOME MKT
11 April 1994
AMGEN OPENS CHINESE OFFICES
21 March 1994
BIOTECHNOLOGY INVESTMENT STRATEGIES
14 March 1994
AMGEN IN CHINA
28 February 1994
IMMUNEX AIMS FOR THREE DRUGS IN CLINIC IN 1994
21 February 1994
NEW STOCK COMMENT
14 February 1994
RESTRUCTURING CHARGES DEPRESS LILLY AND E KODAK
14 February 1994
AMGEN APPOINTMENT
7 February 1994
AMGEN APPOINTMENT
24 January 1994
WORLD HEMATOLOGY MARKET FORECASTS
24 January 1994
LENOGRASTIM LAUNCHED IN UK
17 January 1994
BETAFECTIN STARTS PHASE III TRIALS
17 January 1994
ROCHE RECORDS 11% INCREASE IN '93 SALES
17 January 1994
NEW YORK STOCK COMMENT
10 January 1994
NEUROTROPHIC FACTORS: CHANGING NEUROLOGY
20 December 1993
SANDOZ UNVEILS IL-6 TRIAL DATA
20 December 1993
UK BIOTECH STOCKS STARTING TO MATURE
13 December 1993
NEW YORK STOCK COMMENT
6 December 1993
DRUGS FOR CANCER IMMUNOLOGY IN 1992
29 November 1993
COMBINING SCF AND G-CSF THERAPY
15 November 1993
CURRENCY EXCHANGE FACTOR HITS US 3rd QTR
8 November 1993
NEW YORK STOCK COMMENT
25 October 1993
FIRST NINE MONTHS STRONG FOR ROCHE
25 October 1993
NEW YORK STOCK COMMENT
11 October 1993
FILGRASTIM BACKED FOR NEW INDICATION
11 October 1993
US BIOTECH PRODUCTS IN R&D (Cont'd from last issue)
4 October 1993
BIOTECH STOOCK VS CLINTON HEALTH REFORM
4 October 1993
PMA WARNING ON FUTURE OF BIOTECHNOLOGY
27 September 1993
NEW YORK STOCK COMMENT
27 September 1993
AUSTRALIAN NO TO AMGEN'S NEUPOGEN
27 September 1993
AMGEN KIRIN JOINT AGREEMENT
6 September 1993
NEW YORK STOCK COMMENT
16 August 1993
THE BIOTECH INDEX AND TRADING STRATEGIES
16 August 1993
AMGEN SETS UP HONG KONG/CHINA BASE
16 August 1993
GLAXO IN R&D DEAL WITH REGENERON
2 August 1993
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
NICHE MARKETING IN THE BIOTECH INDUSTRY
26 July 1993
PHASE I TRIALS FOR BDNF
19 July 1993
ROCHE PHARMA HEALTHY IN 1st HALF
19 July 1993
PHARMA DIRECTION FOR BRITISH BIO-TECHNOLOGY
19 July 1993
LENOGRASTIM GIVEN CPMP PANEL BACKING
12 July 1993
NEW YORK STOCK COMMENT
5 July 1993
NEW YORK STOCK COMMENT
28 June 1993
BIOTECH PATENT BILL VIEWED
21 June 1993
NEW YORK STOCK COMMENT
31 May 1993
NEW YORK STOCK COMMENT
24 May 1993
FIRST RECOMBINANT STEM CELL FACTOR TRIALS
24 May 1993
GENETICS AND AMGEN SETTLE DISPUTE
17 May 1993
STRONG GROWTH BY US PHARMA COs IN 1st QTR
10 May 1993
NEW YORK STOCK COMMENT
26 April 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
NEW YORK STOCK COMMENT
12 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
FILGRASTIM RESULTS
29 March 1993
NEW YORK STOCK COMMENT
22 March 1993
PHARMACEUTICAL DESIGN: EPITOPE SELECTION
15 March 1993
AUSTRALIA TO RESTRICT NEUPOGEN
15 March 1993
NEW YORK STOCK COMMENT
8 March 1993
CLINTON RECOVERY PLAN: DRUG SECTOR TARGETED
1 March 1993
IMCLONE HEADING FOR COMMERCIALIZATION
1 March 1993
AMGEN NEW CANCER RESEARCH CENTER
22 February 1993
NEW YORK STOCK COMMENT
15 February 1993
US 4th QTR SHOWS NOT ALL COMPANIES STRONG
15 February 1993
CHUGAI AND KIRIN SETTLE EPO DISPUTE
8 February 1993
US COMPANIES IN BIOTECH LINK-UP
18 January 1993
ROCHE 1992 SALES RISE BY 13%
18 January 1993
ABPI CODE OF PRACTICE LATEST REPORT
21 December 1992
IN DEFENSE OF BIOTECHNOLOGY
7 December 1992
US DRUG ANALYSTS VIEW CLINTON WIN
9 November 1992
CLINTON: NO SHORT TERM CHANGES EXPECTED
9 November 1992
US CHEMICAL/PHARMA COS' POOR PERFORMANCE
9 November 1992
AMGEN APPOINTMENT
2 November 1992
SPECTRUMSTOCKCOMMENT
26 October 1992
FILGRASTIM: NO PLACE IN ABMT?
12 October 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
NEW YORK STOCK COMMENT
5 October 1992
USE OF GROWTH FACTORS IN AIDS MANAGEMENT
7 September 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
ABPI CODE OF CONDUCT REPORT
3 August 1992
New York: stock comment
6 July 1992
AMGEN HAS WORLD LEADERSHIP AIM
22 June 1992
Stock Comment: Tokyo
15 June 1992
Boehringer drug banned in germany
8 June 1992
stock commentary: New York
1 June 1992
AMGEN/CHUGAI PATENT DISPUTE RESOLVED
25 May 1992
STOCK MARKET COMMENTARY:TOKYO
25 May 1992
STOCK MARKET COMMENTARY: NEW YORK
18 May 1992
ANALYSTS OPTIMISTIC ON IMMUNEX
4 May 1992
US DRUGMAKERS TAX PENALIZATION
27 April 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
AMGEN SETS UP IN AUSTRALIA
27 January 1992
AMGEN FILES SUIT AGAINST CHUGAI
27 January 1992
ITALIAN CO IN DEAL WITH AMGEN
27 January 1992
REVISIONS FOR US ORPHAN DRUG ACT?
27 January 1992
US BIOTECH INVESTMENT OPTIONS
20 January 1992
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
